# CanariaBio

Source: https://onco.cc/companies/canariabio/  
OnCo record `canariabio` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

CanariaBio is a South Korean biotech that took over oregovomab, an antibody against the ovarian cancer marker CA-125 that is given with chemotherapy to prime an immune response against the tumour.

## Summary

CanariaBio acquired the oregovomab programme from OncoQuest of Edmonton, Canada. Oregovomab (MAb-B43.13) binds circulating CA-125 and, given at the same time as carboplatin and paclitaxel, forms immune complexes that induce CA-125-specific T-cell responses. After a phase 2 trial suggested longer progression-free survival, the phase 3 FLORA-5 trial in newly diagnosed advanced ovarian cancer read out in 2024 without meeting its primary endpoint.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- Also known as: OncoQuest; OncoQuest Pharmaceuticals; 카나리아바이오
- Tags: drug-maker
- HQ: Seongnam
- Type: biotech

## Connected records

- drugs: [Oregovomab](https://onco.cc/drugs/oregovomab/)
- trials: [A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.](https://onco.cc/trials/nct05335993/), [Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer](https://onco.cc/trials/nct04938583/), [Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery](https://onco.cc/trials/nct04498117/), [Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer](https://onco.cc/trials/nct05605535/)

---
JSON: https://onco.cc/api/v1/entities/canariabio.json